ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
ASP Isotopes Inc. files its annual report describing a rapid expansion into advanced isotopes, nuclear fuels, helium and LNG, and construction services. The company began commercial isotope production in Pretoria in 2025 and is targeting initial shipments of enriched C-14, Si-28 and Yb-176 in 2026.
ASP acquired Renergen, gaining South Africa’s only onshore petroleum production right and the Virginia Gas Project, which produces LNG and high‑grade helium. Through subsidiary QLE, it is developing HALEU nuclear fuel and lithium enrichment, backed by a $22.0 million conditional loan and long‑term HALEU supply agreements with TerraPower.
The report details 51% ownership of radiopharmacy PET Labs, the ECNP pharmacy acquisition, early‑stage investments in IsoBio and Opeongo, and a controlling interest in Skyline, adding Hong Kong civil engineering services. ASP plans to separate QLE as a standalone public company via a future listing and equity distribution to existing stockholders.
ASP Isotopes Inc. announced that Executive Chairman and CEO Paul Mann will host a business update conference call and webcast on April 13, 2026, at 8:00 AM ET. Investors and the public can join via toll and toll-free numbers or a live webcast, with a replay available on the company’s website.
The company develops proprietary isotope enrichment technologies, including its Aerodynamic Separation Process and Quantum Enrichment, to supply critical materials for nuclear medicine, advanced semiconductors, and nuclear energy. The announcement also highlights that management may discuss forward-looking statements during the call, which are subject to significant risks and uncertainties.
ASP Isotopes Inc. submitted a Form 12b-25 notification stating it could not file its annual report on Form 10-K for the period ended December 31, 2025 within the prescribed time. The company signed the notice on March 31, 2026 and cites Rule 12b-25 procedures.
ASP Isotopes Inc: An amendment to a Schedule 13G/A states that The Vanguard Group reports 0% beneficial ownership of the issuer's common stock as of the amendment filing. The filing explains an internal realignment of Vanguard subsidiaries on January 12, 2026 that led to disaggregated reporting; Vanguard lists 0 shares and no voting or dispositive power.
Renergen, whose Virginia Gas Project underpins ASPI’s interest, outlines extensive risks around expanding Phase 2. The project demands large, uncertain capital outlays, complex permitting and reliance on conditional debt facilities of up to $500 million from DFC and $250 million from Standard Bank that carry stringent conditions.
The company faces exposure to inflation, higher interest rates, supply chain constraints, power and water shortages, and South Africa–specific socio‑economic and political risks. Operational challenges span drilling complexity, pipeline construction, contractor dependence, cybersecurity, data‑privacy compliance, and concentrated single‑site exposure. High leverage, covenant limits and potential impairment if projects underperform could pressure liquidity and future results.
ASP Isotopes, through its wholly owned subsidiary Quantum Leap Energy, has begun a strategic collaboration with the University of Bristol to design a state-of-the-art lithium laser enrichment research facility in the UK. Bristol will lead a roughly four-month initial phase focused on feasibility and detailed technical design.
The work covers concept design, engineering specifications and safety reviews, progressing to completion of RIBA Stage 4 technical design. If the feasibility assessment is positive, the parties intend to build the facility at a suitable off-campus University of Bristol site for research commissioned and funded by Quantum Leap Energy, targeting advanced lithium-6 and lithium-7 enrichment for next-generation fission and fusion nuclear fuels.
ASP Isotopes reports a major milestone at its Virginia Gas Project, completing all wells required for Phase 1 of the Renergen Helium Project about four months ahead of schedule. Drilling results from the Phase 1C campaign indicate reservoir gas flow rates that meet or exceed earlier type-curve estimates, easing historic constraints on plant utilisation and helium production.
The Phase 1 drilling program has now achieved the required cumulative nameplate flow rate, meaning remaining work to reach full output is largely engineering-focused. Some new wells are delivering gas flow rates up to 16 times those of certain earlier wells, and the company plans to tie these into the processing plant over the coming months. After planned completion of Phase 1 during 2026, ASP Isotopes expects production of 2,500 GJ per day of LNG and 58 MCF per day of liquid helium, rising after Phase 2 to 34,000 GJ per day of LNG and 895 MCF per day of liquid helium.
The update comes as global helium supply tightens due to the closure of the Strait of Hormuz and reported damage at Ras Laffan in Qatar, which supplied about 2.3 billion scf of helium in 2025. The company highlights South Africa’s geopolitical neutrality and backing from the U.S. International Development Finance Corporation as advantages for positioning the Virginia Gas Project as a significant new source of liquid helium.
ASP Isotopes Inc. announced that CEO Paul Mann will participate in a fireside chat at Canaccord Genuity’s 2nd Annual CG Virtual Sustainability Summit on March 12, 2026, at 3:20 p.m. ET. The event will be held virtually and focuses on sustainability-related topics.
A live audio webcast of the presentation will be available in the Investors section of the company’s website, with a replay accessible within 48 hours. The company highlights its work on proprietary isotope enrichment technologies for applications in nuclear medicine, advanced semiconductors, and nuclear energy, and includes extensive cautionary language about forward-looking statements and related risks.
ASP Isotopes Inc. COO Robert Ainscow reported an open-market sale of 8,438 shares of common stock. The transaction occurred on March 6, 2026 at a weighted average price of $5.439 per share.
The sale was a "sell to cover" under a Rule 10b5-1 trading plan adopted on June 9, 2025 to cover tax withholding obligations from vesting restricted stock awards. After this transaction, Ainscow directly owns 1,537,817 ASP Isotopes common shares.
Ainscow Robert filed a Form 144 reporting a proposed sale of 300,000 shares of common stock of Independent Trading Group (ITG) Inc., described as acquired as compensation (Restricted Stock Award) on 09/06/2024. The filing also lists securities sold during the past three months: 8,438 shares on 12/08/2025 with an amount shown of 52,340.91.